Discontinued products
Discontinued Product name |
PIP Code |
Date of discontinuation |
---|---|---|
AMOXIL CAPSULE 250MG 3X7 | 453-951 | Early 2019 |
AMOXIL CAPSULE 500MG 3X7 | 453-969 | Early 2019 |
AMOXIL PAED 100MG/ML 1X20ML | 10835 | Mid 2020 |
AUG SUSP 457MG/5ML 1X70ML | 288-5556 | Early 2019 |
AUGMENTIN INJ VIAL 1.2G 1X10ML | 2342616 | Nov 2021 |
AUGMENTIN VIAL 500/100MG 10x25ML_GB | 171330 | Nov 2021 |
CERVARIX VACCINE PFS 0.5ML 500ML | 3308301 | March 2021 |
CELSENTRI 25MG TABLETS | 4052999 | Aug 2021 |
CELSENTRI 75MG TABLETS | 4052981 | Aug 2021 |
CUTIVATE CREAM 0.05% 30G | 3470101 | Nov 2020 |
CUTIVATE CREAM 0.05% 15G | 2075216 | Nov 2020 |
CUTIVATE OINTMENT 0.005% 15G | 2247146 | Nov 2020 |
ENGERIX B VIALS x 1 | 153171 | Nov 2020 |
ENGERIX B VIALS x 10 | 876144 | Nov 2020 |
FORTUM INJECTION 1G | 381988 | FEB 2022 |
FORTUM INJECTION 2G | 385278 | FEB 2022 |
FORTUM INJECTION 500MG | 434092 | FEB 2022 |
HALERAID 120 INHALATION DEVICE 1 | 211-8115 | Mid 2020 |
HALERAID 200 INHALATION DEVICE 1 | 162-743 | Mid 2020 |
HAVRIX AD VIAL x 1 | 3988656 | Late 2019 |
HAVRIX JUNIOR MONODOSE VACCINE VIAL | 3988664 | Late 2019 |
ISOTREXIN GEL 2%/0.05% 30G | 2407781 | Late 2019 |
PENTOSTAM INJ 100ML x 1 | 214395 | Mid 2019 |
RABIPUR PFS X 1 | 4044921 | March 2021 |
ROTARIX LIQUID PFS 1DX1 | 2555860 | Late 2019 |
SYNFLORIX PF SYRINGE 1X1 | 3535127 | Early 2019 |
TELZIR ORAL SUSP 50MG/ML x 225ML | 3101193 | July 2021 |
TIMENTIN VIALS 3.2G x 4 | 4192 | Nov 2020 |
VENTOLIN NEBULE 2.5MG 20x2.5ML | 204982 | Jan 2022 |
VENTOLIN NEBULE 5MG 20X2.5ML | 188714 | Dec 2021 |
ZANTAC SYRUP 300ML | 413229 | Dec 2020 |
ZANTAC INJ 25MG/ML 5x2ML | 453720 | Dec 2020 |
ZINACEF 1.5G/26 HP- GB X1 | 389361 | FEB 2022 |
ZINACEF 250MG/17 HP-GB X5 | 379552 | FEB 2022 |
ZINACEF 750MG/17 HP GB X5 | 379578 | FEB 2022 |
ZINNAT SUSPENSION 125MG/5ML 70ML UK-GSK | 110023 | FEB 2022 |
ZINNAT TABLETS 125MG X 14 UK-GSK | 226183 | FEB 2022 |
ZINNAT TABLETS 250MG X 14 UK-GSK | 226969 | FEB 2022 |
ZOVIRAX EYE OINTMENT 3%W/W 1X4.5G | 455-329 | Early 2019 |
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.